Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 637523, 5 pages
Research Article

HS1,2 Ig Enhancer Alleles Association to AIDS Progression in a Pediatric Cohort Infected with a Monophyletic HIV-Strain

1Department of Biology, University of Rome “Tor Vergata,” 00133 Rome, Italy
2Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3
3University Department of Pediatrics, DPUO, Unit of Immune and Infectious Diseases, Children’s Hospital “Bambino Gesù,” 00165 Rome, Italy
4Istituto Mario Negri Sud, 66030 Chieti, Italy
5International Training Unit, Children’s Hospital “Bambino Gesù,” 00165 Rome, Italy
6San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy
7Department of Biomedicine and Prevention, University of Rome “Tor Vergata,” 00133 Rome, Italy
8ProxAgen Ltd., 1505 Sofia, Bulgaria

Received 28 February 2014; Revised 28 April 2014; Accepted 28 April 2014; Published 20 May 2014

Academic Editor: Esteban Martinez

Copyright © 2014 Carla Montesano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Alteration in the humoral immune response has been observed during HIV infection. The polymorphisms of enhancer HS1,2, member of the 3′ regulatory region of the Ig heavy chain cluster, may play a role in the variation of the humoral response leading to pathological conditions. To assess the role of the HS1,2 polymorphic variants in the progression of AIDS, the HS1,2-A allelic frequencies were investigated in a cohort of HIV infected pediatric subjects from a nosocomial outbreak with a monophyletic strain of HIV. From a total group of 418 HIV infected children in the outbreak cohort, 42 nonprogressors and 31 progressors without bias due to antiretroviral therapy were evaluated. HS1,2 allele *1 has been associated with nonprogressors (allelic frequency: 51.19% versus 33.87% in progressors, OR 0.5, and , while allele *2 has been associated with progression (allelic frequency: 48.39% versus 30.95% in nonprogressors, OR 2.1, and . Further, only subjects carrying allele *2 in absence of allele *1, either in homozygous condition for allele *2 [nonprogressors 2/42 (4.76%), Progressors 7/31 (22.58%), OR 5.8, and or in combination with other allelic variants [nonprogressors 7/42 (16.67%), Progressors 13/31 (41.93%), OR 3.61, and , have been associated with HIV progression to AIDS. In conclusion, while the HS1,2 allele *1 has a protective effect on HIV progression when present, allele *2 is associated with progression toward AIDS when allele *1 is absent.